MEDIA RELEASE PR41117
NeoStem Appoints Distinguished Businessman as New President and Managing Director NeoStem China
NEW YORK, Sept. 7 /PRNewswire-AsiaNet/ --
Dr. Ian Zhang has over 20 years of experience in the biotech
field
NeoStem, Inc. (NYSE Amex: NBS) ("NeoStem" or the "Company"), an
international biopharmaceutical company with operations in the U.S. and
China, today announced that it has appointed Ian Zhang, Ph.D., MBA, as the
new president and managing director of NeoStem (China), Inc. Dr. Zhang is the
former Head of Asia Pacific Integration at Life Technologies, where he served
on the steering committee managing the acquisition and integration of Applied
BioSystems. He is also the former Head of Corporate Development (Asia
Pacific) for Invitrogen responsible for growth strategy and acquisitions and
integrations, where he had also managed the acquisition and integration of
BioAsia, Dynal, Zymed, and Caltech by Invitrogen. Dr. Zhang also served as
the President and General Manager for Dynal Biotech (Beijing) Ltd. (a wholly
owned subsidiary of Invitrogen Corporation).
Dr. Zhang received his MBA at the University of Chicago, Graduate School
of Business and holds a Ph.D. in biotechnology from Simon Fraser University.
He continued his education as a postdoctoral fellow at Yale University School
of Medicine. His professional focus is on growth strategy and
acquisitions/integrations in the biotech field particularly related to
biotech growth in Asia. "Now that we have launched our business in China and
are generating revenues, we are excited to add such a seasoned individual to
our senior management team to lead the expansion effort," said Dr. Robin
Smith, CEO and Chairman of the Board of NeoStem.
Dr. Zhang commented, "I am excited to join an innovative, forward-looking
company like NeoStem and be part of the team of experts to help bring
advanced stem cell technologies into China and develop a business in China in
a regulatory environment that is supportive of Stem Cells and a healthcare
environment that can benefit from technologies to treat diseases using stem
cell based therapy."
About NeoStem, Inc.
NeoStem, Inc. is engaged in the development of stem cell-based therapies
and building of a network of adult stem cell collection centers in the U.S.
and China that are focused on enabling people to donate and store their own
(autologous) stem cells for their personal use in times of future medical
need. The Company is also the licensee of various stem cell technologies,
including a worldwide exclusive license to VSEL(TM) Technology which uses
very small embryonic-like stem cells, shown to have several physical
characteristics that are generally found in embryonic stem cells, and is
pursuing the licensing of other technologies for therapeutic use. NeoStem's
majority-controlled Chinese pharmaceutical operation, Suzhou Erye,
manufactures and distributes generic antibiotics in China. For more
Forward-Looking Statements
This press release contains forward-looking statements within the meaning
of the Private Securities Litigation Reform Act of 1995. Forward-looking
statements reflect management's current expectations, as of the date of this
press release, and involve certain risks and uncertainties. Forward looking
statements include the future of VSEL TM Technology as a viable treatment
option, about which no assurances can be given. The Company's actual results
could differ materially from those anticipated in these forward-looking
statements as a result of various factors. Factors that could cause future
results to materially differ from the recent results or those projected in
forward-looking statements include the "Risk Factors" described in the
Company's Annual Report on Form 10-K filed with the Securities and Exchange
Commission on March 31, 2010, as well as other periodic and other filings
made with the Securities and Exchange Commission. The Company's further
development is highly dependent on future medical and research developments
and market acceptance, which is outside its control.
NeoStem, Inc.
Robin Smith, CEO
Phone: +1 (212) 584-4174
E-mail: rsmith@neostem.com
SOURCE: NeoStem, Inc.
CONTACT: Robin Smith, CEO, NeoStem, Inc.
+1-212-584-4174,
rsmith@neostem.com
NEWS 
